tiprankstipranks
Trending News
More News >

Coya Therapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $16 price target The firm says the company’s anti-inflammation platform utilizes a disease pathway agnostic approach to increase the number and function of regulatory T cells. The evidence supporting a therapeutic anti-inflammatory benefit of Coya’s low dose IL-2 is strong, the analyst tells investors in a research note.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1